Erin Miller

Boston College — United States

Medicine · Health Sciences

18h-index1.8kcitations58works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(17), Cancer Cells and Metastasis(9), Protease and Inhibitor Mechanisms(8), Cancer Immunotherapy and Biomarkers(6), Peptidase Inhibition and Analysis(6)

Publications58 total

Targeting CSF1R to overcome myeloid cell suppression in CART therapy
Blood·2025Open Access
Lactate does not replace glucose for maintaining the viability of mouse and human glioma cells
ONCOLOGIE·2025Open Access
Response variability to exercise (REVISE): Study rationale, design and methods
Contemporary Clinical Trials Communications·2025Open Access
Changes in Body Composition in Relation to Metabolic Syndrome: A Compositional Analysis in Adults with Overweight and Obesity
Medicine & Science in Sports & Exercise·2025· 1 cited
Lactate cannot replace glucose for maintaining the viability of mouse and human glioma cells
2025Open Access
Supplementary Figure 4 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 6 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 6 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 3 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Data from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 1 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 4 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 7 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 2 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 2 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 5 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 5 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 1 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Data from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
Supplementary Figure 7 from Patient-Derived Tumor Xenograft Study with CDK4/6 Inhibitor Plus AKT Inhibitor for the Management of Metastatic Castration-Resistant Prostate Cancer
2024Open Access
page 1 of 3Next →

Frequent Co-authors

Derek C. Radisky(21), John A. Copland(19), Justyna Trynda(17), Aylin Alasonyalılar Demirer(17), Matthew L. Pawlush(15), Laura A. Marlow(14), Adam M. Kase(13), James L. Miller(13), Joachim L. Petit(13), Michael T. Barrett(13), Yumei Zhou(13), Ephraim E. Parent(13), Hancheng Cai(13), Joshua A. Knight(13), Jacob J. Orme(13), Jordan Reynolds(13), William F. Durham(13), Thomas Metz(13), Nathalie Meurice(13), Brandy Edenfield(13)